Yoshiga Yasuhiro, Shimizu Akihiko, Yamagata Toshihiko, Hayano Tomoko, Ueyama Takeshi, Ohmura Masato, Itagaki Kazuo, Kimura Masayasu, Matsuzaki Masunori
Division of Cardiovascular Medicine, Department of Medical Bioregulation, Yamaguchi University School of Medicine, Ube, Japan.
Circ J. 2002 Nov;66(11):1024-8. doi: 10.1253/circj.66.1024.
Bepridil is effective for intractable cardiac arrhythmia, but in rare cases will induce torsades de pointes (TdP) associated with QT interval prolongation. Beta-blockers will effectively prevent TdP in some clinical settings, so the effect of beta-blocker on the change in QT interval, QT dispersion and transmural dispersion of repolarization (TDR) induced by bepridil was investigated in 10 patients (7 male, 3 female; 62+/-6 years old) with intractable paroxysmal atrial fibrillation. The QTc interval, QTc dispersion and TDR were measured before and after 1 month of administration of bepridil, and then a beta-blocker was added and the QTc interval, QTc dispersion and TDR re-measured 1 month later. Bepridil significantly prolonged the QTc interval (0.42+/-0.05 to 0.50+/-0.08; p<0.01), and increased both the QT dispersion (0.07+/-0.05 to 0.14+/-0.08; p<0.01) and TDR (0.10+/-0.04 to 0.16+/-0.05; p<0.01). The addition of a beta-blocker decreased the QTc interval (0.50+/-0.08 to 0.47+/-0.04; p=0.09) and significantly decreased both the QTc dispersion (0.14 +/-0.08 to 0.06+/-0.02; p<0.01) and TDR (0.16+/-0.05 to 0.11+/-0.04; p<0.001). Compared with the control, the combination therapy significantly prolonged the QTc interval, but did not increase either QTc dispersion or TDR, and so was effective in all patients with intractable AF. The findings suggest that beta-blocker reduces the increase in QT dispersion and TDR induced by bepridil, and combined therapy with bepridil and beta-blocker might thus be useful for intractable atrial fibrillation.
苄普地尔对难治性心律失常有效,但在罕见情况下会诱发与QT间期延长相关的尖端扭转型室性心动过速(TdP)。β受体阻滞剂在某些临床情况下可有效预防TdP,因此,本研究在10例(7例男性,3例女性;年龄62±6岁)难治性阵发性心房颤动患者中,研究了β受体阻滞剂对苄普地尔所致QT间期、QT离散度和跨壁复极离散度(TDR)变化的影响。在给予苄普地尔1个月前后测量QTc间期、QTc离散度和TDR,然后加用β受体阻滞剂,1个月后再次测量QTc间期、QTc离散度和TDR。苄普地尔显著延长QTc间期(从0.42±0.05至0.50±0.08;p<0.01),并增加QT离散度(从0.07±0.05至0.14±0.08;p<0.01)和TDR(从0.10±0.04至0.16±0.05;p<0.01)。加用β受体阻滞剂后,QTc间期缩短(从0.50±0.08至0.47±0.04;p=0.09),QTc离散度和TDR均显著降低(分别从0.14±0.08至0.06±0.02;p<0.01和从0.16±0.05至0.11±0.04;p<0.001)。与对照组相比,联合治疗显著延长了QTc间期,但未增加QTc离散度或TDR,因此对所有难治性房颤患者均有效。研究结果表明,β受体阻滞剂可降低苄普地尔所致的QT离散度和TDR增加,苄普地尔与β受体阻滞剂联合治疗可能对难治性心房颤动有用。